Previous 10 | Next 10 |
Gracell Biotechnologies press release (NASDAQ:GRCL): Q4 GAAP EPS of -$0.06 beats by $0.10. As of December 31, 2021, the Company had RMB1,832.6 million (US$287.6 million) in cash and cash equivalents and short-term investments. For further details see: Gracell Biotechnologies GAAP EPS of...
Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022 Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human investigator-initiated trial (IIT) in China in B-cell malignanci...
PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the t...
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 PR Newswire Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZ...
PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of canc...
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform Abstract providing early first-in-human data on GC502 accepted for presentation at American Association for Cancer Research (AACR) Annual Meeting 2022 PR Newswire SUZHOU, C...
China's National Medical Products Administration approved Pfizer's Paxlovid, an oral COVID-19 therapy for adults who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease. The approval is conditional, based on Pfizer providing additional data. Shanghai S...
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma Candidate dual-targeting B cell maturation antigen (BCMA) and CD19 expands Gracell's FasTCAR autologous, next-d...
Gainers: Tritium DCFC DCFC +82%. US Ecology ECOL +69%. Moving iMage Technologies MITQ +29%. Solid Power (NASDAQ:SLDP) +23%. Kaival Brands Innovations Group (NASDAQ:KAVL) +23%. Doximity DOCS +23%. Gracell Biotechnologies (NASDAQ:GRCL) +20%. Bakkt Holdings (NYSE:BKKT) +20%. ...
SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...